Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months

Osteoporosis International

Volumn 25, Issue 5, 2014, Pages 1633-1642

  Anastasilakis, A D ^a   Polyzos, S A ^b   Makras, P ^c   Gkiomisi, A ^a   Bisbinas, I ^a   Katsarou, A ^d   Filippaios, A ^e   Mantzoros, C S ^e  

^a 424 General Army Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d Hellenic Military School of Medicine   (Greece)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone metabolism; Denosumab; Fracture; Irisin; Osteoporosis; Teriparatide

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; DENOSUMAB; FIBRONECTIN BINDING PROTEIN; IRISIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; FIBRONECTIN; FNDC5 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; BONE MASS; BONE METABOLISM; CELL DIFFERENTIATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MUSCLE MASS; OSTEOBLAST; OSTEOCLASTOGENESIS; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; BLOOD; BONE DENSITY; CASE CONTROL STUDY; COMPLICATION; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; PROCEDURES;

ABSORPTIOMETRY, PHOTON; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; CREATININE; FEMALE; FEMUR NECK; FIBRONECTINS; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PARATHYROID HORMONE; TERIPARATIDE;

EID: 84899640297     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2673-x     Document Type: Article

References (18)

1. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018
2. Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P (2012) Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag 8:295-306
3. Hodsman A, Bauer D, Dempster D et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703
4. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457-465
5. Boström P, Wu J, Jedrychowski MP et al (2012) A PGC1-α- dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463-468
6. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725-1738
7. Staiger H, Böhm A, Scheler M et al (2013) Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived 'browning' factor irisin, determines insulin sensitivity. PLoS One 8:e61903
8. Polyzos SA, Kountouras J, Shields K, Mantzoros CS (2013) Irisin: a renaissance in metabolism? Metabolism 62:1037-1044
9. Rahman S, Lu Y, Czernik PJ, Rosen CJ, Enerback S, Lecka-Czernik B (2013) Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology 154(8):2687-2701
10. Zhang J, Wu Y, Yu L, Meng S, Zhang L, Huang M, Tu Q, Chen JJ (2012) Exercise strengthens bone through myokine irisin. J Bone Miner Res 27 (Suppl 1). Available at http://www.asbmr.org/Itinerary/PresentationDetail.aspx?id= a8a0e3b4-1ca5-4b3e-b35a-307b043e1458. Accessed 14-15 October 2012
11. DiVasta AD, Gordon CM (2013) Exercise and bone: where do we stand? Metabolism 62:1714-1717
12. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769-E778
13. Wen MS, Wang CY, Lin SL, Hung KC (2013) Decrease in irisin in patients with chronic kidney disease. PLoS One 8:e64025
14. Ensrud KE, Ewing SK, Fredman L, Hochberg MC, Cauley JA, Hillier TA, Cummings SR, Yaffe K, Cawthon PM, Group SoOFR (2010) Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab 95:5266-5273
15. Murad MH, Elamin KB, Abu Elnour NO et al (2011) Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:2997-3006
16. Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD (2013) Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 79:499-503
17. Anastasilakis AD, Polyzos SA, Goulis DG, Slavakis A, Efstathiadou Z, Kita M, Koukoulis G, Avramidis A (2008) Endogenous intact PTH is suppressed during teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis. Endocr J 55:613-616
18. Boström PA, Fernández-Rea JM, Mantzoros CS (2014) Irisin in humans: recent advances and questions for future research. Metabolism 63:178-180